Phenominer Database Results (33 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
SHRSP/A3NCrl cardiac output controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 9 86.0 ml/min 6.0 18.0 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107000 3073
SHRSP/A3NCrl cardiac output controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 89.0 ml/min 6.0 18.97 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107001 3073
SHRSP/A3NCrl ejection fraction controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 67.0 % 1.0 3.16 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107027 3073
SHRSP/A3NCrl stroke volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 9 245000.0 ml 14000.0 42000.0 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107032 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 48.0 % 14.0 28.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107297 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 385.0 nmol/l 89.0 267.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107305 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 100.0 % 2.0 6.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107094 3073
SHRSP/A3NCrl timed urine volume controlled sodium content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. urine output male 99 days-148 days 9 79.0 ml/d 11.0 33.0 metabolic cage urine volume measurement method 86400.0 0 8 week HSFD plus treatment 8 week high salt high fat plus treatment 107055 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 91.0 % 8.0 24.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107076 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 407.0 nmol/l 158.0 316.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107304 3073
SHRSP/A3NCrl end-diastolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 9 0.36 ml 0.02 0.06 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106969 3073
SHRSP/A3NCrl urine albumin excretion rate controlled sodium content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. urine albumin amount male 99 days-148 days 9 142.0 mg/d 42.0 126.0 urine microalbumin analysis 86400.0 0 8 week HSFD plus treatment 8 week high salt high fat plus treatment 107061 3073
SHRSP/A3NCrl end-systolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 9 111000.0 ml 11000.0 33000.0 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106975 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 0.08 umol/l 0.02 0.05 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107082 3073
SHRSP/A3NCrl heart left ventricle weight to body weight ratio controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. heart left ventricle mass male 134 days-141 days 9 3.06 mg/g 0.07 0.21 transthoracic echocardiography 0.0 0 3-5 cardiac cycles LV mass calculated from 2-D images with area-length method 107038 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 4 0.05 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 107081 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 0.26 10E-7mol/l 0.15 0.3 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107087 3073
SHRSP/A3NCrl end-diastolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 0.38 ml 0.02 0.07 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106970 3073
SHRSP/A3NCrl stroke volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 259000.0 ml 13000.0 41109.61 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107033 3073
SHRSP/A3NCrl ratio of survivors to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. life span trait male 141 days-148 days 8 46.0 % Kaplan-Meier estimate 0.0 0 107043 3073
SHRSP/A3NCrl end-systolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 120000.0 ml 9000.0 28460.5 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106976 3073
SHRSP/A3NCrl heart left ventricle weight to body weight ratio controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. heart left ventricle mass male 134 days-141 days 10 2.85 mg/g 0.1 0.32 transthoracic echocardiography 0.0 0 3-5 cardiac cycles LV mass calculated from 2-D images with area-length method 107039 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 111.0 % 3.0 6.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107093 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 59.0 % 4.0 12.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107298 3073
SHRSP/A3NCrl body weight controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. body mass male 134 days-141 days 10 345.0 g 14.0 44.27 body weighing method 0.0 0 HSFD +3.0 mg/kg/day BAY 60-4552 106964 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 4 93.0 % 8.0 16.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107075 3073
SHRSP/A3NCrl body weight controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. body mass male 134 days-141 days 9 328.0 g 6.0 18.0 body weighing method 0.0 0 HSFD +0.3 mg/kg/day BAY 60-4552 106963 3073
SHRSP/A3NCrl ejection fraction controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 9 69.0 % 2.0 6.0 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107026 3073
SHRSP/A3NCrl ratio of survivors to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. life span trait male 141 days-148 days 8 69.0 % Kaplan-Meier estimate 0.0 0 107044 3073
SHRSP/A3NCrl mean arterial blood pressure controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. arterial blood pressure trait male 99 days-141 days 9 serial mean 175.0 mmHg 1.0 3.0 vascular indwelling catheter method femoral artery 432000.0 0 10 seconds every 5 minutes for 24hr high salt high fat diet +8 wk treat group baseline and after treatment 107050 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 0.19 10E-7mol/l 0.05 0.15 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107088 3073
SHRSP/A3NCrl timed urine volume controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. urine output male 99 days-148 days 9 56.0 ml/d 10.0 30.0 metabolic cage urine volume measurement method 86400.0 0 8 week HSFD plus treatment 8 week high salt high fat plus treatment 107056 3073
SHRSP/A3NCrl urine sodium excretion rate controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. urine sodium amount male 99 days-148 days 9 16.0 mEq/d 2.0 6.0 urine sodium analysis 86400.0 0 8 week HSFD plus treatment 8 week high salt high fat plus treatment 107066 3073